Three-Year Oral Clodronate Treatment Does Not Impair Mineralization of Newly Formed Bone—A Histomorphometric Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Three-Year Oral Clodronate Treatment Does Not Impair Mineralization of Newly Formed Bone—A Histomorphometric Study

Published:2005-08 Issue:2 Volume:77 Page:84-90
ISSN:0171-967X
Container-title:Calcified Tissue International
language:en
Short-container-title:Calcif Tissue Int

Author:

Saarto T.,Taube T.,Blomqvist C.,Vehmanen L.,Elomaa I.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s00223-004-0262-2.pdf

Reference27 articles.

1. LONG-TERM CONTROLLED TRIAL WITH DIPHOSPHONATE IN PATIENTS WITH OSTEOLYTIC BONE METASTASES

2. Oral clodronate in breast cancer patients with bone metastases: a randomized study

3. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

4. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

5. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-07-09

2. Lessons from bone histomorphometry on the mechanisms of action of osteoporosis drugs;Marcus and Feldman's Osteoporosis;2021

3. Bisphosphonates and other bone agents for breast cancer;Cochrane Database of Systematic Reviews;2017-10-30

4. Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline;Journal of Clinical Medicine;2013-12-17

5. Os, cible thérapeutique (RPC 2013);Oncologie;2013-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3